OUR SOLUTION
What is the PARIS® Test?
SEngine’s CLIA-certified platform tests patients’ tumor samples with a panel of up to 42 drugs selected for each individual patient from a comprehensive library of approximately 200 curated and validated oncology drugs. The PARIS® Test is a “functional assay” that tests a panel of oncology drugs to identify potentially actionable treatments.
These drugs include:
FDA-approved targeted therapies
FDA-approved chemotherapies
FDA-approved and non-FDA approved therapies being evaluated in clinical trials
AVAILABLE NOW
Serving Patients, Research Partners and Pharmaceuticals
The PARIS® Test is the antidote for today's failing standard of care. DNA sequencing alone predicts effective treatment an estimated 15% of the time. The PARIS® Test delivers personalized treatment options for solid tumors. As a CLIA-certified lab, SEngine provides actionable reports directly to oncologists today.
Patient Impact
SEngine Precision Medicine is having an impact on patient’s lives. Hear testimonials about the PARIS Test from Nobel laureate scientist, Dr. Lee Hartwell, and Ingrid Kolstoe, patient and survivor.
As Seen IN
